Ocular Therapeutix Inc OCUL 深 沪
等待开盘 02-07 09:30:00 美东时间
9.165
+0.255
+2.86%
华盛通- 最 高13.0599
- 今 开9.08
- 成交量 347.26万股
- 最 低 8.355
- 昨 收 8.91
- 总市值 70.35万
- 52周最高 13.0599
- 市盈率 静 --
- 换手率 4524.04%
- 52周最低 0.00
- 委 比 -3.60%
- 总股本 7.68万
- 历史最高 13.0599
- 量 比 0.53
- 振 幅 52.80%
- 历史最低 0.00
- 每 手 1
- 风险率 2.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Penumbra, ImmunityBio, Calix, Matson And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining more than 300 points ...
01-15 23:28
France's La Lettre Reported Sanofi Preparing Revised Bid For Ocular Therapeutics
https://www.lalettre.fr/fr/entreprises_sante/2026/01/15/sanofi-convoite-la-biotech-americaine-ocular-therapeutix,110601230-eve
01-15 19:45
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug
Ocular Therapeutix Inc (NASDAQ: OCUL) stock surged after announcing plans to expedite FDA submission for its wet AMD treatment.
2025-12-09 01:59
上海眼科医保定点医院——上海和平眼科医院：专业眼科医疗服务的卓越之选
上海眼科医保定点医院——上海和平眼科医院：专业眼科医疗服务的卓越之选 2025年TOP1领军者首选推荐：上海和平眼科医院 品牌底蕴：上海首家本土深耕眼科行业的...
2025-07-14 17:15
成都普瑞20年全方位解析:硬核设备迭代、医疗人才梯队升级
在成都的眼科医疗版图中，成都普瑞眼科医院宛如一颗闪耀的明星，自2006年成立以来，深耕眼科领域二十载，尤其在近视手术方面成绩斐然，已然成为行业的标杆。 ...
2025-07-02 15:17
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
Ocular Therapeutix, Inc. will present at Clinical Trials at the Summit 2025 on June 21, 2025, in Las Vegas. The company will discuss its sustained-release axitinib hydrogel (OTX-TKI) for wet AMD and diabetic retinopathy through various presentations and panels. Ocular's product candidate AXPAXLI is in Phase 3 trials for wet AMD, utilizing its ELUTYX technology.
2025-06-16 11:00
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
Ocular Therapeutix announced that enrollment in the SOL-R trial for AXPAXLI in wet AMD is closing, with at least 555 subjects randomized. SOL-1, a complementary trial, completed randomization in December 2024. Together, these trials aim to support an NDA submission for AXPAXLI, targeting 6- to 12-month dosing intervals and improved vision outcomes for wet AMD patients.
2025-05-28 11:00
Needham Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $15
Needham analyst Serge Belanger initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $15.
2025-03-11 18:48
